The pharmaceutical company said the 130,000-square-foot building will allow scientists to collaborate better on research for small molecules and synthetic peptides.
While the ultimate outcome remains far from certain, the study is a bright spot—if a tenuous one—in the search for a treatment for Alzheimer’s, where more than 100 experimental drugs have failed.
As the organization’s leaders plan for the next two decades, they’re targeting the 3.3 miles of the White River that runs through their property for new experiences and attractions.
Indianapolis Power & Light has agreed not to raise the fixed monthly rate it charges most of its residential customers, under a rate-case settlement it reached with the Indiana Office of Utility Consumer Counselor and other stakeholders.
The Indianapolis-based pharmaceutical company said the division’s headquarters would remain in Greenfield after the spinoff and that no job cuts are planned.
The run-up in share price seems to reflect investor sentiment that the Indianapolis drugmaker has turned a corner after more than a decade of struggling to launch new medicines.
While the California Consumer Privacy Act of 2018 targets the protection of personal information of California residents only, the law will have far greater impact in two material ways.
Civic leaders breathed a sigh of relief on July 24 when Eli Lilly and Co. announced it planned to spin off its Greenfield-based animal-health unit, Elanco, in an initial public offering rather than selling it outright. Indianapolis-based Lilly had announced last October that it was exploring strategic options for the business. It’s a phrase that […]
Indiana Utility Consumer Counselor Bill Fine is tasked with making sure Hoosier households and business aren’t overcharged for electricity, natural gas, water or wastewater.
The drug, launched in 2014, is one of Lilly’s fastest-growing medicines, but its fate could hinge on the results of another clinical trial for heart benefits. The Indianapolis-based drugmaker plans to release results later this year.
The university said it has hired 33 research faculty to help under the “Grand Challenges” program in precision health, an initiative it rolled out two years ago.
Elanco Animal Health Inc. could see a market value of as much as $20 billion, according to Bloomberg Intelligence. At that valuation, a share sale could raise as much as $5 billion.
After decades of being starved of innovative treatments for serious conditions like cancer, diabetes and kidney disease, China’s 1.4 billion people are becoming a prime target for Eli Lilly and other pharmaceutical companies.
The American Medical Association recently called on regulators to monitor competition among the three drugmakers who control the market—Indianapolis-based Eli Lilly and Co., Denmark-based Novo Nordisk and Paris-based Sanofi.
